Durable intracranial response to multidisciplinary treatment in triple-negative breast cancer: case report
Open Access
- 2 April 2026
- journal article
- case report
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 19 (2) , 89-91
Abstract
Summary: This clinical case describes the course of a woman with metastatic triple negative breast cancer involving the brain, lungs, and lymph nodes who was enrolled in the phase II clinical trial TUXEDO‑2 investigating datopotamab deruxtecan (Dato-DXd) for the treatment of active (newly diagnosed or progressing after prior local treatment) brain metastases. After six cycles of therapy, she discontinued the study to undergo neurosurgical resection followed by radiotherapy of a single progressing cerebellar metastasis causing compression of the fourth ventricle, while all other intra- and extracranial lesions demonstrated a significant response to Dato-DXd. The patient subsequently continued Dato-DXd treatment off-trial and remained on therapy for a total duration of 2.5 years at the time of last follow-up.Keywords
Funding Information
- Medizinische Universität Wien
This publication has 11 references indexed in Scilit:
- LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trialAnnals of Oncology, 2025
- Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patientsJNCI: Journal of the National Cancer Institute, 2025
- Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNature Medicine, 2024
- 187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)ESMO Open, 2024
- Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 yearsEuropean Journal of Cancer, 2022
- The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysisNeuro-Oncology, 2020
- Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialJournal of Clinical Oncology, 2020
- Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)Neuro-Oncology, 2017
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraThe Breast, 2013
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008